风湿病与关节炎
風濕病與關節炎
풍습병여관절염
Rheumatism and Arthritis
2014年
12期
14-17
,共4页
孙助民%孙杰%吴宁%魏善斋%张以来
孫助民%孫傑%吳寧%魏善齋%張以來
손조민%손걸%오저%위선재%장이래
关节炎,类风湿%青白散%甲氨蝶呤%美洛昔康
關節炎,類風濕%青白散%甲氨蝶呤%美洛昔康
관절염,류풍습%청백산%갑안접령%미락석강
arthritis,rheumatoid%Qingbai Powder%methotrexate%meloxicam
目的：观察青白散联合甲氨蝶呤及美洛昔康治疗类风湿关节炎的临床疗效及安全性。方法：将64例类风湿关节炎患者随机分为治疗组34例和对照组30例。对照组给予口服甲氨喋呤每次10 mg，每周1次；美洛昔康每次7.5 mg，每日2次；治疗组在对照组治疗的基础上加用青白散，每次2 g，每日3次，冲服。两组美洛昔康疗程为8周，余药疗程为12周。观察两组患者治疗前，治疗第12周关节症状改善程度及药物不良反应。结果：治疗后，治疗组ACR20、ACR50、ACR70分别为88.24%、70.59%、52.94%，对照组ACR20、ACR50、ACR70分别为73.33%、46.67%、33.33%。两组比较，差异有统计学意义（P<0.05）。治疗组关节肿胀、关节压痛、晨僵时间、红细胞沉降率、DAS28评分等临床和实验室指标改善均优于对照组，差异有统计学意义（P<0.05）；两组安全性比较，差异无统计学意义（P>0.05）。结论：青白散联合甲氨蝶呤及美洛昔康治疗类风湿关节炎，能很好地缓解患者的关节症状；且不良反应发生率低，患者依从性高。
目的：觀察青白散聯閤甲氨蝶呤及美洛昔康治療類風濕關節炎的臨床療效及安全性。方法：將64例類風濕關節炎患者隨機分為治療組34例和對照組30例。對照組給予口服甲氨喋呤每次10 mg，每週1次；美洛昔康每次7.5 mg，每日2次；治療組在對照組治療的基礎上加用青白散，每次2 g，每日3次，遲服。兩組美洛昔康療程為8週，餘藥療程為12週。觀察兩組患者治療前，治療第12週關節癥狀改善程度及藥物不良反應。結果：治療後，治療組ACR20、ACR50、ACR70分彆為88.24%、70.59%、52.94%，對照組ACR20、ACR50、ACR70分彆為73.33%、46.67%、33.33%。兩組比較，差異有統計學意義（P<0.05）。治療組關節腫脹、關節壓痛、晨僵時間、紅細胞沉降率、DAS28評分等臨床和實驗室指標改善均優于對照組，差異有統計學意義（P<0.05）；兩組安全性比較，差異無統計學意義（P>0.05）。結論：青白散聯閤甲氨蝶呤及美洛昔康治療類風濕關節炎，能很好地緩解患者的關節癥狀；且不良反應髮生率低，患者依從性高。
목적：관찰청백산연합갑안접령급미락석강치료류풍습관절염적림상료효급안전성。방법：장64례류풍습관절염환자수궤분위치료조34례화대조조30례。대조조급여구복갑안첩령매차10 mg，매주1차；미락석강매차7.5 mg，매일2차；치료조재대조조치료적기출상가용청백산，매차2 g，매일3차，충복。량조미락석강료정위8주，여약료정위12주。관찰량조환자치료전，치료제12주관절증상개선정도급약물불량반응。결과：치료후，치료조ACR20、ACR50、ACR70분별위88.24%、70.59%、52.94%，대조조ACR20、ACR50、ACR70분별위73.33%、46.67%、33.33%。량조비교，차이유통계학의의（P<0.05）。치료조관절종창、관절압통、신강시간、홍세포침강솔、DAS28평분등림상화실험실지표개선균우우대조조，차이유통계학의의（P<0.05）；량조안전성비교，차이무통계학의의（P>0.05）。결론：청백산연합갑안접령급미락석강치료류풍습관절염，능흔호지완해환자적관절증상；차불량반응발생솔저，환자의종성고。
Objective:To observe the clinical efifcacy and safety of Qingbai Powder combined with methotrexate and meloxicam in treatment of rheumatoid arthritis.Methods:64 cases with rheumatoid arthritis were randomly divided into a treatment group(34 cases)and a control group(30 cases).The control group were given orally methotrexate,10 mg each time,once a week;and meloxicam,7.5 mg each time, twice a day;while the treatment group,based on the treatment of the control group,were treated with Qingbai Powder,2 g each time,3 times a day.Meloxicam treated 8 weeks,and others 12 weeks.The two groups were observed before and after treatment 12 weeks on the aspects of reactions and joint symptom improvement.Results:After treatment,the ACR20,ACR50 and ACR70 of the treatment group were respectively 88.24%,70.59%and 52.94%,while those of the control group were respectively 73.33%,46.67% and 33.33%.The difference between the two groups was statistically signiifcant (P<0.05).The treatment group was better than the control group on the clinical and laboratory indexes such as joint swelling,joint tenderness,morning stiffness time,erythrocyte sedimentation rate and DAS28 score,the difference being statistically significant(P < 0.05);the difference of safety between the two groups was not signiifcant(P>0.05).Conclusion:Qingbai Powder combined with methotrexate and meloxicam can be very good to ease joint symptom in the treatment of rheumatoid arthritis,with low incidence rate of adverse reactions and high dependence of patients.
